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Early cancer detection and disease stratiﬁcation or classiﬁcation are
critical to successful treatment. Accessible, reliable, and informative
cancer biomarkers can be medically valuable and can provide some
relevant insights into cancer biology. Recent studies have suggested
improvements in detecting malignancies by the use of speciﬁc
extracellular microRNAs (miRNAs) in plasma. In chronic lymphocytic
leukemia (CLL), an incurablehematologic disorder, sensitive, early, and
noninvasive diagnosis and better disease classiﬁcation would be very
useful for more effective therapies. We show here that circulating
miRNAs can be sensitive biomarkers for CLL, because certain extracel-
lular miRNAs are present in CLL patient plasma at levels signiﬁcantly
different from healthy controls and from patients affected by other
hematologic malignancies. The levels of several of these circulating
miRNAs also displayed signiﬁcant differences between zeta-associ-
ated protein 70 (ZAP-70)+ and ZAP-70− CLL. We also determined that
the level of circulating miR-20a correlates reliably with diagnosis-to-
treatment time. Network analysis of our data, suggests a regulatory
network associated with BCL2 and ZAP-70 expression in CLL. This hy-
pothesis suggests the possibility of using the levels of speciﬁcmiRNAs
in plasma to detect CLL and to determine the ZAP-70 status.
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Chronic lymphocytic leukemia (CLL) is the most common he-matologic malignancy affecting adults in Western countries,
even though the true incidence remains uncertain (1). Like many
other cancers, the diagnosis of the disease is often delayed due to
the lack of symptoms in the early stages. The abnormal expression
of certain T-cell markers by CLLB cells, namely CD5, CD184, and
ZAP-70, have been helpful in stratifying the disease (2). For ex-
ample, overall survival is signiﬁcantly better for ZAP-70− than for
ZAP-70+ cases. ZAP-70 is primarily a T- and NK-cell marker in
differentiated cells and also plays a role in the transition of pro-B
to pre-B cells in the bone marrow (3). Thus, ZAP-70+ CLL seems
to represent less differentiated cell populations and has a more
aggressive cancer phenotype. Although CLL remains an incurable
disorder, early stage detection and treatment can control disease
progression, whereas late stage patients are often unresponsive
to various treatments (4). Even though CLL often presents with
a heterogeneous pathology in the clinic, most patients receive
a few standardized treatments, primarily on the basis of limited
clinical parameters such asRai orBinet staging, which classify CLL
patients on the basis of the spreading of the disease and its cyto-
genetic characterization, underlining the need for more in-
formative diagnosticmarkers with better clinical signiﬁcance (5, 6).
Since the recent reports of circulating, extracellular micro-
RNAs (miRNAs) in plasma, they have become an attractive
source of new nucleic acid-based biomarkers (7). MicroRNAs
belong to the class of small noncoding RNA molecules (∼20
nucleotides) and affect biological functions either by post-
transcriptional silencing or stimulating transcript degradation. It
is estimated that the expression of 20–30% of protein-coding
genes may be affected by either one or multiple miRNAs (see ref.
10 for example). The levels of miRNAs are precisely controlled in
the cells to assure proper cellular function and differentiation (8);
aberrant expression of miRNA are commonly observed in path-
ological processes, including oncogenesis (9). One commonly
observed chromosomal aberrations in CLL is the deletion of
chromosomal 13q14.3, a region containing miR-15a and miR-16,
which suggests, but does not prove, the involvement of miRNAs
in the pathogenesis of CLL (10). In addition, an aberrant cellular
miRNA expression proﬁle in CLL B cells has been described
and the changes correlate well with prognostic factors including
ZAP-70 expression status and IgVHmutations inCLL patients (11).
Recent studies also demonstrated the decrease of miR-29c and
miR-223 levels in cells during the progression of the disease (12).
Prior studies have reported the presence of tumor-derived, low
molecular weight RNAs (miRNAs and other noncoding RNAs)
in plasma of patients with solid tumors (13–15). In the present
study, our aim was to explore the possibility of using the changes
of extracellular miRNA spectra in CLL plasma samples to pro-
vide more accurate assessment of the disease and improve the
molecular classiﬁcation of CLL. On the basis of our ﬁndings,
speciﬁc plasma miRNA signatures are associated with CLL and
these miRNAs could constitute new and informative biomarkers
in CLL diagnosis and disease stratiﬁcation.
Results
We investigated the changes of plasma miRNA spectrum from
a cohort of CLL patient plasma samples (SI Appendix, Table S1
summarizes clinical information on cohort). The CLL prognosis
markers, ZAP-70 expression level and IgVH mutation status
from the corresponding B cells were also determined. To identify
miRNA with potential clinical applications, we initially proﬁled
miRNA spectra from nine pooled samples including pooled
healthy control, six pooled CLL samples based on disease stages
and ZAP-70 expression status, a pooled multiple myeloma (MM)
plasma, and a pooled sample with hairy cell leukemia (HCL).
The miRNAs with altered expression levels in each set were then
veriﬁed with individual samples in the cohort, which contains 31
patient and 17 healthy control samples.
Signiﬁcant Number of miRNAs Are Present in Plasmas of Patients with
B-Cell–Related Malignancies. Using unsupervised hierarchical clus-
tering, the samples were grouped into three major groups, the
ZAP-70+ samples, the ZAP-70− samples, and a group containing
normal, MM, and HCL samples based on the results of plasma
miRNA proﬁle (SI Appendix, Fig. S1). Similar to prior ﬁndings in
plasma from patients with solid tumors, a higher number of de-
tectable circulating miRNAs was found in CLL plasma samples
(average n = 296) compared with normal, control plasma (n =
230), a 28% increase. A similar trend was also observed in other
hematologic malignancy samples tested: an MM plasma sample
had 256 detectablemiRNAs, an 11% increase, and anHCL sample
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had 260 detectable miRNA species, a 13% increase compared with
normal. The plasma samples from ZAP-70+ CLL patients had
a higher number of detectablemiRNAs than theZAP-70− samples:
333 detectable miRNA species in ZAP-70+ vs. 256 detectable
miRNA species in ZAP-70− samples (SI Appendix, Fig. S2).
Examining the list of the 20 most abundant miRNAs in all our
plasma samples, a signiﬁcant number of miRNA species in-
cluding miR-150, miR-19b, and miR-92a, miR-223, miR-320,
miR-484, and miR-17 were highly abundant in all of the samples
(SI Appendix, Table S2). miR-223 was the most abundant
miRNA species in normal human plasma as well as plasma from
HCL and MM patients; however, in ZAP-70− CLL samples the
miR-150 was the most abundant.
Levels of Speciﬁc Circulating miRNAs Can Be Used to Identify
Different Hematological Malignancies. From the global miRNA
Table 1. Discriminating CLL from healthy controls (P < 0.01) and other hematologic malignancies with circulating miRNA
miRNA
Mean fold
change ± SEM† AUC value‡
Mean fold
change ± SEM† P value§
Mean fold
change ± SEM† P value§
Mean fold
change ± SEM† P value§
Discovery set B-CLL (n = 41) Controls (n = 8) MM (n = 7) HCL (n = 4)
miR-150 61.83 ± 16.70 7.80E-01 1.09 ± 0.39 1.10E-03 0.43 ± 0.12 1.00E-03 1.63 ± 0.14 1.20E-03
miR-150* 29.07 ± 7.20 8.10E-01 1.00 ± 0.03 2.30E-03 1.43 ± 0.26 2.70E-03 0.00 NA
miR-29a 24.27 ± 6.79 9.20E-01 1.07 ± 0.15 1.50E-03 0.69 ± 0.12 1.30E-03 1.12 ± 0.58 1.60E-03
miR-135a* 20.81 ± 5.62 8.40E-01 1.17 ± 0.26 1.60E-03 1.24 ± 0.24 1.60E-03 1.27 ± 0,25 1.70E-03
miR-195 8.77 ± 1.09 9.50E-01 1.34 ± 0.43 8.90E-08 1.62 ± 0.42 2.00E-07 1.25 ± 0.37 7.00E-08
miR-21 8.76 ± 1.81 8.80E-01 1.24 ± 0.11 2.00E-04 1.74 ± 0.45 5.10E-04 3.35 ± 1.00 1.40E-02
miR-93 8.47 ± 1.53 9.10E-01 1.56 ± 0.62 1.30E-04 2.68 ± 0.62 2.70E-03 3.34 ± 1.36 2.55E-02
miR-486–5p 7.85 ± 1.07 8.90E-01 1.54 ± 0.51 2.90E-06 3.35 ± 1.63 3.96E-02 2.75 ± 0.72 6.40E-04
miR-20a 7.22 ± 0.78 9.20E-01 1.34 ± 0.46 7.70E-08 2.24 ± 0.87 5.30E-04 0.99 ± 0.33 8.40E-09
miR-16–1 6.45 ± 0.76 8.80E-01 1.63 ± 0.65 4.20E-05 1.84 ± 0.77 3.80E-04 2.72 ± 0.58 1.20E-03
miR-106a 6.43 ± 0.92 9.20E-01 1.28 ± 0.37 4.70E-06 3.38 ± 1.37 3.78E-02 1.98 ± 0.99 2.38E-02
miR-483–5p 5.90 ± 1.39 7.30E-01 1.18 ± 0.26 3.90E-03 0.00 NA 1.26 ± 0.15 3.90E-03
miR-222 5.53 ± 0.86 9.10E-01 1.21 ± 0.25 1.50E-05 1.12 ± 0.30 1.50E-05 1.48 ± 0.74 3.10E-03
miR-15a 3.03 ± 0.44 6.70E-01 1.08 ± 0.16 2.30E-04 1.07 ± 0.18 3.30E-04 2.20 ± 0.72 3.67E-01
Validation set B-CLL (n = 31) Controls (n = 17)
miR-150 21.59 ± 4.17 1.19 ± 0.14 2.00E-04
miR-150* 28.94 ± 1.46 1.46 ± 0.22 2.00E-04
miR-29a 6.89 ± 1.41 1.41 ± 0.23 1.62E-02
miR-135a* 13.52 ± 1.57 1.57 ± 0.35 2.90E-03
†Ct values were normalized by using synthetic spiked-in C. elegans miRNAs and fold changes were calculated relative to the average expression in plasma of
healthy controls by using the 2^(-∆∆Ct) method.
‡AUC values were obtained from the ROC curves assessing the predictive power of individual miRNAs.
§P values were calculated by two-sided t test for each group relative to CLL patients.
Fig. 1. Detection of CLL by
the levels of speciﬁc miR-
NAs in plasma. Plasma levels
of selected miRNAs were
determined by RT-qPCR in
41 CLL patients and eight
healthy controls from the
discovery cohort. Ct values
were normalized by using
synthetic spiked-in Caeno-
rhabditis elegans miRNAs
and fold changes were cal-
culated relative to the av-
erage expression in plasma
of healthy controls by using
the 2^(-∆∆Ct) method. The
line indicates a 100% speci-
ﬁcity threshold. P values
were obtained from two-
sided t test.
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proﬁling results with pooled plasma samples, several miRNA
species showed distinct proﬁles between CLL and HCL or MM
samples (SI Appendix, Fig. S3 A and B). For example, the levels of
miR-363 and miR-708 were lower in HCL but higher in CLL and
showed no signiﬁcant difference compared with normal levels in
MM (SI Appendix, Fig. S3A), whereas miR-34a andmiR-564 were
lower in MM but higher in CLL with no signiﬁcant changes in
HCL compared with normal levels (SI Appendix, Fig. S3B).
Among the CLL samples, there were a number of miRNA species
that showed differences between the ZAP-70+ and ZAP-70−
samples (SI Appendix, Table S3). For instance, the levels of
miR-205, miR-29a, and miR-652 are higher in ZAP-70− samples
compared with ZAP-70+ plasma samples, whereas miR-19b and
miR-144* were higher in ZAP-70+ samples. A number ofmiRNAs
also showed progressive changes along with the severity of the
disease; for example, miR-30e concentration in plasma continues
to decrease as disease progresses, whereas the miR-363 level
continues to increase as disease progresses, regardless of their
ZAP-70 expression status (SI Appendix, Fig. S4). Although not all
B-cell–derived malignancies were tested, these miRNAs have the
potential to be used to distinguish different types of B-cell ma-
lignancies (like HCL and MM) or to classify CLL patients by
stage, once they have been validated on independent cohorts.
To assess the potential of using miRNAs as CLL biomarkers,
we chose 27 miRNAs that showed changes to be studied in in-
dividual samples, including 8 normal, 41 CLL, 7 MM, and 4 HCL
plasma samples. Among the selected miRNAs, 14 of the 27 could
clearly discriminate CLL samples from the three other groups
(normal, MM, and HCL) with high conﬁdence (P < 0.01, listed
in Table 1). The overall distribution of levels of four of these
miRNAs (miR-29a, miR-150*, miR-195, and miR-222) between
CLL and normal are shown as examples in Fig. 1. miRNAs that
showed the most difference between CLL and normal samples in
the discovery cohort (miR-150, -150*, -29a, and -135a*), and
were therefore most promising, were conﬁrmed with a second
independent validation cohort (also in Table 1), which consisted
of 31 CLL patients and 17 healthy controls (SI Appendix, Table
S1 for patient information).
The levels of these selected 27 miRNAs were also determined
in the corresponding CLL B cells in each patient. Using un-
supervised hierarchical clustering, these miRNAs clearly sepa-
rated the cells and plasmas (SI Appendix, Fig. S5) from each other.
The proﬁles are distinct and clearly different. The cells, in general,
had higher levels of miRNAs of most corresponding species in the
plasma, except for miR-135a*, miR-451, and miR-486–5P (SI
Appendix, Fig. S5). The cellular miRNA spectra further grouped
the samples into two subgroups (groups 1 and 2; SI Appendix,
Fig. S5); however, there was no clear segregation of samples by
either the stage of CLL or the ZAP-70 expression status. The
plasma samples were also separable into subgroups, groups 3, 4,
and 5. Group 4 had all of the controls and most of the ZAP-70+
samples, whereas the other two groups were mixed with different
stages of the CLL samples. The controls and ZAP-70+ samples
appear together in group 4, but there was a clear separation be-
tween them (SI Appendix, Fig. S5).
The correlation among the levels of circulating miRNAs across
different samples was further assessed by calculating the Pearson-
moment correlation coefﬁcient, r, using an internal tool, called
“CoExpress.” As shown in SI Appendix, Table S4, four miRNA
clusters were identiﬁed with r > 0.600 and P < 0.0001. A very
strong correlation was observed between the levels of miR-93 and
miR-106a (r=0.906, P=3.33E-16), two closely residing miRNAs
on human chromosome 9q. The same correlation was seen for
miR-15a andmiR-16–1, whose genes are close together on human
chromosome 13q. Another large cluster, cluster 2, grouped miR-
483–5p, miR-29a, and miR-150* (r > 0.900 and P < 1.0E-12), but
these miRNAs are not colocated in the genome.
ZAP-70 Expression Status Affects the miRNA Spectra in Both Cells and
Plasma. Among the 27 miRNAs selected, most of them showed
higher levels in the plasma of the CLL patients, compared with
healthy controls, but most showed no signiﬁcant changes in the
corresponding B cells (Table 2). Even though the changes for
some of the miRNAs, such as miR-150*, miR-638 in plasma, and Ta
bl
e
2.
Th
e
le
ve
lo
f
pl
as
m
a
an
d
co
rr
es
po
nd
in
g
B-
ce
ll
m
iR
N
A
s
ba
se
d
on
ZA
P-
70
st
at
us
an
d
di
se
as
e
se
ve
ri
ty
Sa
m
pl
e
ZA
P-
70
st
at
us
B
CL
L
st
ag
e
le
t- 7e
m
iR
-
10
6a
m
iR
-
12
25
–
5p
m
iR
-
13
5a
*
m
iR
-
14
8a
m
iR
-
15
0*
m
iR
-
15
a
m
iR
-
16
–
1
m
iR
-
18
1a
m
iR
-
18
5
m
iR
-
19
5
m
iR
-
19
8
m
iR
-
20
a
m
iR
-
21
m
iR
-
22
1
m
iR
-
22
2
m
iR
-
23
b
m
iR
-
29
a
m
iR
-
33
1–
5p
m
iR
-
34
a
m
iR
-
45
1
m
iR
-
48
3–
5p
m
iR
-
48
6–
5p
m
iR
-
62
5
m
iR
-
63
8
m
iR
-
93
m
iR
-
93
9
N
or
m
al
pl
as
m
a
7.
86
12
.5
0
6.
57
11
.0
9
8.
60
5.
16
6.
90
16
.4
4
5.
31
9.
53
9.
09
5.
13
12
.1
1
12
.9
9
7.
45
9.
56
5.
94
11
.2
0
5.
47
7.
47
15
.7
4
5.
58
13
.4
5
5.
17
7.
16
10
.7
7
5.
49
B
CL
L
pl
as
m
a
−
0
9.
72
15
.3
6
7.
27
14
.9
9
8.
77
8.
44
8.
66
19
.2
9
5.
72
12
.3
4
12
.4
6
5.
45
15
.2
0
15
.7
6
9.
74
11
.2
2
5.
58
15
.3
0
5.
85
7.
06
18
.0
2
7.
51
16
.7
9
5.
67
7.
80
13
.9
5
7.
21
B
CL
L
pl
as
m
a
−
I–
II
9.
63
14
.9
7
7.
28
14
.3
8
8.
76
8.
86
8.
20
18
.6
8
5.
72
11
.7
8
12
.3
5
5.
61
15
.0
3
15
.9
2
9.
60
11
.3
5
5.
60
15
.6
3
5.
55
7.
48
16
.8
2
7.
95
15
.9
9
5.
77
7.
84
13
.5
0
8.
34
B
CL
L
pl
as
m
a
−
III
–
IV
9.
62
14
.5
2
7.
51
15
.9
2
9.
90
9.
47
8.
03
18
.6
1
5.
14
10
.9
6
11
.6
4
6.
76
14
.6
3
16
.6
5
8.
88
11
.3
9
5.
14
16
.0
5
5.
98
6.
85
16
.3
7
8.
18
15
.3
1
6.
08
8.
38
12
.7
7
8.
69
B
CL
L
pl
as
m
a
+
0
9.
09
13
.7
3
7.
48
11
.5
6
8.
53
5.
61
6.
64
18
.2
8
5.
05
10
.5
3
11
.0
9
4.
80
13
.5
0
13
.6
7
8.
08
10
.9
8
5.
47
12
.3
9
5.
67
6.
90
16
.2
5
5.
85
15
.3
0
4.
83
7.
38
12
.2
7
6.
82
B
CL
L
pl
as
m
a
+
II
8.
98
14
.0
4
6.
37
12
.0
0
8.
96
5.
58
6.
73
18
.0
1
5.
63
11
.1
4
11
.1
7
4.
83
13
.5
9
13
.6
9
8.
70
10
.8
1
5.
06
12
.4
4
5.
43
6.
68
16
.6
8
5.
48
15
.2
4
5.
04
6.
94
12
.8
6
6.
12
B
CL
L
pl
as
m
a
+
III
9.
07
14
.7
2
7.
32
10
.9
8
8.
72
6.
28
7.
55
17
.4
7
6.
05
10
.5
3
11
.5
3
5.
64
14
.4
1
14
.1
1
9.
32
12
.0
0
6.
14
12
.5
7
6.
01
8.
22
16
.2
8
6.
53
16
.0
6
5.
91
7.
67
13
.6
3
7.
26
N
or
m
al
ce
ll
20
.5
6
20
.1
4
6.
57
13
.2
6
16
.0
2
16
.0
1
17
.9
5
23
.2
1
18
.0
1
16
.1
0
15
.6
5
5.
32
19
.4
5
22
.5
6
18
.4
6
19
.2
6
12
.4
5
21
.9
1
11
.0
2
13
.3
3
11
.9
8
9.
87
14
.2
4
12
.0
3
8.
27
19
.8
9
13
.3
7
B
CL
L
ce
ll
−
0
20
.3
2
19
.4
0
9.
17
12
.9
6
15
.8
9
16
.3
1
16
.6
3
22
.5
9
15
.8
9
14
.6
8
16
.4
6
6.
42
18
.9
9
21
.5
1
16
.7
8
18
.3
4
10
.9
2
21
.9
8
12
.1
8
14
.4
3
9.
88
11
.0
8
14
.9
5
11
.6
5
10
.3
1
18
.6
7
15
.9
2
B
CL
L
ce
ll
−
I–
II
20
.2
3
19
.6
7
7.
97
12
.1
3
16
.5
3
16
.2
8
17
.0
1
22
.8
3
13
.7
9
13
.9
5
16
.6
9
5.
47
19
.4
5
22
.1
0
15
.4
2
18
.1
2
9.
80
22
.4
5
11
.3
2
15
.4
6
9.
74
9.
34
14
.9
5
11
.3
0
9.
16
18
.3
2
1 5
.1
6
B
CL
L
ce
ll
−
III
–
IV
20
.1
4
19
.6
4
7.
60
12
.3
8
16
.6
2
16
.1
0
17
.3
6
23
.1
0
12
.4
6
13
.8
7
16
.6
8
4.
80
19
.4
7
22
.3
6
15
.8
8
18
.1
8
10
.9
9
22
.2
9
10
.7
7
15
.6
2
9.
96
9.
45
14
.7
5
11
.5
0
9.
18
18
.5
5
14
.1
1
B
CL
L
ce
ll
+
0
21
.1
8
20
.4
2
9.
43
13
.0
8
15
.9
8
15
.8
9
18
.0
8
23
.6
1
16
.6
8
16
.0
5
16
.6
6
6.
46
20
.0
3
22
.7
2
17
.9
6
18
.6
1
11
.8
1
22
.5
4
12
.4
2
15
.3
3
10
.9
6
11
.0
8
14
.9
6
12
.1
3
10
.4
0
19
.8
3
16
.5
5
B
CL
L
ce
ll
+
II
20
.7
4
20
.3
1
8.
91
12
.5
6
16
.8
7
15
.7
0
18
.0
6
23
.3
8
16
.7
7
16
.1
8
16
.6
8
6.
26
19
.8
5
22
.7
3
18
.2
7
19
.0
1
13
.2
6
21
.9
7
12
.3
9
15
.6
6
9.
55
10
.0
1
15
.0
8
11
.9
2
10
.4
5
19
.9
9
15
.4
1
B
CL
L
ce
ll
+
III
20
.4
0
20
.0
8
8.
46
12
.4
1
16
.1
6
15
.9
1
17
.6
5
23
.2
4
15
.6
3
15
.4
4
16
.2
7
5.
99
17
.7
4
22
.6
5
17
.4
8
18
.8
5
11
.7
2
21
.8
3
11
.4
3
15
.1
3
12
.3
3
9.
59
15
.2
3
12
.0
3
9.
79
19
.5
2
15
.0
6
†
Ct
va
lu
es
w
er
e
no
rm
al
iz
ed
by
us
in
g
sy
nt
he
ti
c
sp
ik
ed
-in
C.
el
eg
an
s
m
iR
N
A
s
an
d
th
e
le
ve
ls
of
m
iR
N
A
s
(4
0-
∆C
t
va
lu
es
)
w
er
e
sh
ow
n.
Moussay et al. PNAS | April 19, 2011 | vol. 108 | no. 16 | 6575
M
ED
IC
A
L
SC
IE
N
CE
S
miR-181a in cells, correlate well with disease progression in ZAP-
70− samples, the majority do not show signiﬁcant correlation with
disease progression. Several miRNAs, such as miR-185, miR-221,
miR-222, miR-451, and miR-93, showed opposite changes be-
tween plasma and the corresponding cells, especially in the ZAP-
70− samples (SI Appendix, Fig. S6). This observation of reciprocal
changes of miRNA between intracellular (tissue or cells) and
extracellular (plasma) levels is similar to our previous ﬁndings in
a drug-induced liver injury model (16). The difference between
the two ZAP-70 groups of miRNAs compared with normals can
be greater than 39-fold (for example, a 5.3 cycle number differ-
ence between ZAP-70− stage III–IV and normal plasma for miR-
29a). In general, the ZAP-70− samples showed greater changes in
the miRNA levels in both cells and plasma.
We also validated the changes of the most abundant miRNA
species between ZAP-70+ and ZAP-70− pooled samples, miR-
223 in ZAP-70+ and miR-150 in ZAP-70−, on individual plasma
samples (31 patient and 17 healthy control samples) (SI Appendix,
Fig. S7). Although the level of miR-233 was similar among all of
the samples, there was a signiﬁcant increase in the levels of miR-
150 in ZAP-70− plasma samples. The level of miR-150 increased
with the severity of the diseases in ZAP-70− samples, so there is
staging information associated with this marker.
Assessing the Predictive Value of Circulating miRNAs in CLL Disease
Stratiﬁcation. The predictive power of changes in certain circu-
lating miRNA levels was analyzed by receiver operating charac-
teristic (ROC) curves and the associated area under the curve
(AUC). The changes of circulating miR-195 (AUC = 0.951) or
miR-20a (AUC = 0.920) levels were the best classiﬁers to sepa-
rate CLL patients from healthy controls (Table 1). We tested the
possibility of improving performance by combining the changes of
several miRNAs. When all 14 miRNAs listed in Table 1 were
combined, the AUC value derived from a standard principal
component analysis (PCA) and ROC analyses reached 0.950.
Excellent separation between CLL patients and controls can ac-
tually be reached by using only three of several strongly affected
miRNAs—miR-195, -29a, and -222—in CLL patients; the AUC
value reached 0.982 (SI Appendix, Fig. S8A).
The changes of speciﬁc miRNA levels in plasma can also be used
to predict the clinically important ZAP-70 expression status inCLL
patients (Fig. 2). When combining the levels of several miRNAs—
miR-29a, -483–5p, -195, -185, -135a*, and -15a—it provided good
separation between ZAP-70+ and ZAP-70− samples (AUC =
0.877) (SIAppendix, Fig. S8B). Among themiRNAs, the single best
predictorwasmiR-29a (AUC=0.90) forZAP-70 expression status.
We also tested the possibility of using miRNA to assess the
disease severity, the time interval from diagnosis to treatment
need (the requirement for earlier treatment indicates more se-
vere disease). Using the Kaplan–Meier method, the levels of
miR-20a in plasma were shown to correlate well with the disease
severity (P = 0.0242) (SI Appendix, Fig. S8C), which is similar to
the value obtained by using ZAP-70 directly (P = 0.0205) (SI
Appendix, Fig. S8D). On the basis of this ﬁnding, the level of
miR-20a in plasma can be used as a marker for CLL patient
management, perhaps substituting for the ZAP-70 expression
status in CLL B cells. CLL patients with either a lower level of
miR-20a in plasma or positive ZAP-70 expression status in CLL
cells, will need more aggressive and earlier treatment.
Some CLL cases are associated with mutated IgVH (17). We
therefore examined the IgVH mutation status of 24 CLL patients
directly by sequencing and compared this information with
miRNA levels in plasma, but found no signiﬁcant correlations.
The levels of speciﬁc miRNAs in plasma were also compared
with the absolute lymphocyte count (ALC) in the blood. The
miR-29a, miR-150, miR-150*, and miR-483–5p levels in plasma
showed strong correlations with ALC (r > 0.500 and P value <
0.01) on the basis of Pearson’s correlation coefﬁcients (SI Ap-
pendix, Table S5).
Discussion
The presence of altered miRNA proﬁles in plasma has been
reported for several types of solid tumors (13–15). In association
with other markers, the changes in the levels of speciﬁc circu-
lating miRNAs in plasma offer the potential for high sensitivity
and speciﬁcity in tumor detection and classiﬁcation (13, 18),
because access to plasma markers is certainly more direct and
simple. We investigated here the spectra of miRNAs in plasma
of CLL patients and ﬁnd that speciﬁc circulating miRNAs could
also be used to detect and classify CLL cases. We can extract
a great deal of information about the presence, status, and
stratiﬁcation of CLL from the plasma miRNA. Because miRNAs
are exported from cells under some circumstances (19) the
changes of the most abundant plasma miRNA species from miR-
223 to miR-150 (SI Appendix, Fig. S7) may be the result of the
changing composition of lymphoid cells in circulation. miR-150
is highly expressed in B cells; the quantitative increase of miR-
150 levels in the ZAP-70− CLL plasma correlates well with the
stage of the disease (more B cells in more severe disease stage).
Consistent with our ﬁndings in CLL plasma, miR-150 was pre-
viously reported to increase in ZAP-70− CLL cells (20). Bone
marrow stromal cells also provide key inﬂuences and protection
for CLL B cells (21, 22), which suggests they may play a role in
producing circulating miRNAs in B CLL patients. miR-451,
-135a*, and -486–5p are more abundant in plasma (compared
with B cells), which suggests that a signiﬁcant fraction of these
miRNAs in circulation were released by other cell types, perhaps
including bone marrow stromal cells. This hypothesis raises an
intriguing possible role for circulating miRNAs in CLL. They
could actually be acting as a communication signal between CLL
B cells and other cell types including bone marrow stromal cells.
Further investigations are needed to test this hypothesis.
Fig. 2. Levels of miRNAs in plasma of CLL patients according
to cellular ZAP-70 expression. Thirty-nine CLL plasma samples
were analyzed for the expression of selected miRNAs by RT-
qPCR. The ZAP-70 status of B cells was established by RT-PCR.
Data represent the expression fold changes (mean value ± SE)
relative to healthy controls for both ZAP-70+ and ZAP-70−
groups. Ct values were normalized by using synthetic spiked-in
C. elegans miRNAs and fold changes were calculated relative
to the average expression in plasma of healthy controls by
using the 2^(-∆∆Ct) method. Exact P values from two-sided t test
are presented.
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Several MicroRNAs May Affect Key Networks Determining the
Pathology and Prognosis of CLL Cells. Many potential gene tar-
gets of miRNAs with altered expression patterns in either CLL
cell or plasma (Table 2 and SI Appendix, Table S6) interact with
proteins that are overexpressed in CLL cells such as Bcl-2, Mcl-1,
p27, and Tcl-1 identiﬁed earlier (8, 23–25). miR-483–5p, ele-
vated almost sixfold (2.5 Ct) in plasma of CLL patients, is pre-
dicted to target ERK1/MAPK3, which mediates IL-15–induced
CLL proliferation (26) and drives CLL cell migration and in-
ﬁltration (27). Although most of the miRNA–mRNA inter-
actions are yet to be fully validated, the roles of these plasma
miRNAs in CLL present intriguing biological questions with
medically signiﬁcant implications.
The spectrum of gene expression in the cell is regulated by both
transcription factors and miRNAs. Alterations of the levels of
either of these key elements can lead to profound changes in the
gene expression proﬁle in the cell. Two interesting pathological
characteristics associated with the CLL B cells are the anti-
apoptotic properties associated with up-regulation of the BCL2
gene and shorter survival time with the expression of ZAP-70
gene in CLL B cells (28). To explore the involvement of miRNAs
in these two important features of CLL pathology, we collected
miRNA interacting gene target information [from TargetScan
Human V5.1 (http://www.targetscan.org), transcription factor
binding site information fromMSigDB (http://www.broadinstitute.
org/gsea/msigdb/index.jsp), andUniversity ofCalifornia SantaCruz
genome database (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/
database)] to build a hypothetical miRNA transcription factor-
mediated regulatory network that could explain aspects of BCL2
and ZAP-70 expression.
A small hypothetical regulatory network, containing seven
miRNAs and 13 transcription factors, was constructed, which
might be involved in regulating the expression of BCL2 and ZAP-
70 genes (Fig. 3A). The seven miRNAs in the network all showed
reduced levels in CLL B cells (∼1.5-fold decrease), especially in
the ZAP-70− samples, compared with normal controls. Among
the seven miRNAs, miR-181a and miR-15a are predicted to in-
teract with BCL2 directly or indirectly through transcription fac-
tors that may recognize the promoter region of the BCL2 gene.
The miR-23b and miR-181a may also regulate both BCL2- and
ZAP-70–associated transcription factors through the nuclear re-
ceptor NR6A1 (SI Appendix, Fig. S9). Note that these circuits
driving the expression of BCL2 and ZAP-70 represent coherent
effects, which should exhibit switch-like behavior.
The NR6A1 receptor is encoded by 10 exons spanning a 240-
kb region in the genome, and it is striking to note that two of the
key miR-181 family member miRNAs, miR-181b-2 and miR-
181a-2, are located within the NR6A1 gene in the second intron
with a transcription orientation opposite, with respect to NR6A1
(Fig. 3B). The level of miR-181a in plasma showed little change,
either between the ZAP-70 expression statuses or among dif-
ferent disease stages. However, in the CLL cells, the expression
of miR-181a showed signiﬁcant correlation among different
disease stages in both ZAP-70+ and ZAP-70− samples (Table 2).
Functional transcripts using the opposite strands of the same
genomic sequence have been reported: for example, EIF2A and
SERP1 on chromosome 3, CDSN and PSORS1C1 on chromo-
some 3, and TIMP3 and SYN3 on chromosome 22. The ex-
pression patterns of these “gene pairs” usually show negative
correlations, probably because of regulatory effects and the
possibility of forming unstable double-stranded RNA from the
primary transcripts (29, 30). Lower miR-181a levels should then
imply higher NR6A1 mRNA and protein levels and a higher
transcription rate of the NR6A1 gene. We examined this pre-
diction, and a PCR measurement in ZAP-70+ and ZAP-70−
samples conﬁrmed the higher levels of NR6A1 transcription
factor transcript in ZAP-70+ samples (Fig. 3C). Conﬁrmation of
this prediction is consistent with the proposed network.
About 40% of the miRNAs in the genome are located in the
intronic regions of protein coding transcripts (miRBase www.
mirbase.org). Intronic miRNAs, like all miNRAs, play important
roles in regulating various cellular functions. One of the most
characterized intronic miRNA clusters is the miR-17–92 cluster,
where miRNAs in this cluster played critical roles in normal
tissue development as well as the oncogenesis of several types of
cancers (31, 32). A recent report also showed that an intronic
miRNA, miR-211, which is located in the intron 6 of melastatin,
can promote the invasiveness of melanoma cells (33). Melastatin,
a transient receptor potential calcium-channel family member, is
highly expressed in melanomas in situ and down-regulated in
metastatic melanomas. Silencing the melastatin and its intronic
miRNA, miR-211, seems critical to suppress the metastatic po-
tential for melanoma.
Most of the intronicmiRNAs in the genome use the same strand
of the genomic DNA and are cotranscribed with the host gene.
Besides the example in NR6A1–miR-181 illustrated in this report,
there are a few other examples, such as IARS2–miR-194 and
DNM3–miR-199 that reside on different strands of the genomic
DNA with respect to the host gene. It would be of great interest to
Fig. 3. Putative regulatory network associated with BCL2 and ZAP-70 ex-
pression. (A) The genes and miRNAs involved in the putative regulatory net-
work are indicated. The dashed lines indicate the miRNA–mRNA interaction
and solid lines indicate the transcription factor–promoter interaction. The
red color indicates overexpression of genes or miRNAs compared with
normal; green color indicates lower expression. The miRNA expression levels
in different ZAP-70 expression status are indicated as “+” for ZAP-70 positive
and “−” for ZAP-70 negative samples. The BCL2 was drawn as a dotted line
because the increase of gene expression level was indicated in the literature.
(B) The genomic organizations of the miR-181s and NR6A1. The exons are
indicated as black boxes and the 3′ and 5′ untranslated regions are labeled as
open boxes. The transcription orientation is indicated by arrows. The putative
miRNA target sites are labeled as short gray lines on the Bottom. (C) Box plot
diagrams showing the NR6A1 expression determined by RT-qPCR in CLL sam-
ples according to ZAP-70 status. The Top of the box indicates the 75th per-
centile and the Bottom the 25th percentile. The line in theMiddle represents
the median. The Upper whisker shows the 90th percentile and the Lower the
10th percentile. Circles represent the outliers (ZAP-70− samples, n = 18; ZAP-
70+ samples, n = 15). Exact P value from two-sided t test is shown.
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examine the expression correlation between these miRNAs and
their host mRNAs. The ﬁnding of possible functional relationships
between NR6A1 and miR-181 and melastatin and miR-211 sug-
gests a complex regulatory mechanism on the expression and
processing of the intronic miRNAs and their host mRNAs.
Because the levels of miR-181a went down in both ZAP-70+
and ZAP-70− samples (Table 2), it suggests the involvement of
additional factors on the induction of NR6A1and ZAP-70 genes.
This preliminary evidence is therefore consistent with the model
shown in Fig. 3A and suggests further hypotheses concerning the
network biology of CLL.
The development and validation of miRNA biomarkers should
have signiﬁcant impact in improving early cancer detection, strati-
ﬁcation of disease, enhancing therapeutic successes, and in-
creasing the life expectancy of patients. For example, most tumors
of a particular tissue can be stratiﬁed into distinct types—
depending on the nature of the disease-perturbed combinations
of networks they exhibit. This stratiﬁcation into different tumor
types will be important ultimately for achieving an impedance
match with the proper therapy. We demonstrated here from a
cohort of CLL patients the potential of using circulating miRNA
for both detection of CLL and stratiﬁcation of CLL patients.
Levels for several miRNAs are strongly linked to cellular ZAP-70
expression status (Table 2). The time to treatment is an important
clinical parameter (34) that also did have clear correlation with
miRNA, miR-20a. These ﬁndings raise interesting questions
about the origin and roles of circulating miRNAs in hematologic
malignancies and suggest adopting circulating miRNAs as valu-
able biomarkers for CLL. Whether bone marrow stromal cells or
CLL B cells constitutively produce and export miRNAs remains
unclear and underlines the need to understand the biological
origin and function of these circulating miRNAs. The resultant
biology, including the network hypothesis put forward here, may
clarify the therapeutic as well as diagnostic opportunities in the
control of this disease.
Materials and Methods
Patients. Healthy controls and patients affected by hematologic malignancies
were recruited from a single institution (Centre Hospitalier de Luxembourg)
after obtaining a written informed consent in accordance with the Decla-
ration of Helsinki. The number of patients who participated in the study are
detailed in Dataset S1 and the clinical information of the CLL patients are
described in SI Appendix, Table S1.
Plasma Preparation and B-Cell Isolation. All plasma samples were prepared by
sequential centrifugations, detailed in Dataset S1, from whole blood col-
lected in EDTA.
MicroRNAs Expression Proﬁling in RNA Pools. For miRNA proﬁling, total RNA
was extracted from 300 μL of plasma with the miRNeasy kit (Qiagen) as
described (16). The quality and quantity of RNA were assessed by using an
Agilent 2100 Bioanalyzer.
The RNA samples were pooled according to their disease stage by mixing
equal amounts of RNA from each individual in the group. The miRNA proﬁles
were conducted with Taq miRNA low-density array from Applied Biosystems.
The detailed protocols for miRNA proﬁling and data analysis are described in
Dataset S1.
Analysis of ZAP-70 and Sequence Analysis of IgVH. The ZAP-70 status was
veriﬁed by RT-PCR as described by others (35). The analysis of expressed IgVH
gene was done by PCR followed by sequencing (98% homology as a
threshold) as reported before (36).
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